Market Overview

Peloton Therapeutics Appoints Alan A. Musso Chief Financial Officer

Share:

Peloton Therapeutics, Inc., today announced the appointment of Alan A.
Musso as Chief Financial Officer (CFO), effective September 4, 2018. Mr.
Musso brings significant financial expertise and operational leadership
to Peloton. As Peloton's first CFO, Mr. Musso will be responsible for
corporate financing activities, investor relations, accounting, human
resources, information systems, and operations. He will report to John
A. Josey, Ph.D., Peloton's Chief Executive Officer (CEO).

"We are delighted to welcome Alan to Peloton in this strategic
leadership role as we continue to advance our pipeline of novel oral
HIF-2α inhibitors," said John Josey. "He is an accomplished
biotechnology CFO with an impressive track record of successful public
and private financings, business development and effective team building
at development-stage companies. The Board of Directors and I are
confident he will be an excellent addition to our senior management
team."

Mr. Musso has 30 years of biotechnology and pharmaceutical industry
experience, including capital raising, corporate partnering, finance,
strategy, and the financial stewardship of publicly-traded companies. He
joins Peloton from Bellicum Pharmaceuticals, Inc., a biopharmaceutical
company focused on cellular cancer immunotherapies, where he served as
CFO and Treasurer since November 2014 and successfully raised $300
million via an IPO and follow-on financings. Prior to Bellicum, he was
CFO at Targacept where he led its 2006 IPO and multiple public and
private financings. Earlier in his career, he held a variety of key
managerial positions in finance and accounting at Osiris Therapeutics,
Cato Research, Duramed Pharmaceuticals and Pfizer. Mr. Musso is a
Certified Public Accountant (CPA) and began his career with KPMG. Mr.
Musso received a B.S. in Accounting from Saint Mary's College of
California, and a master's degree from the American Graduate School of
International Management.

Peloton's drug discovery and development efforts focus on identifying
novel compounds capable of modulating complex protein-protein
interactions that drive disease which have eluded conventional small
molecule approaches. The company is currently evaluating PT2977,
a once-daily oral inhibitor of HIF-2α, in an international Phase 2 trial
in VHL-associated renal cell carcinoma (RCC) and a Phase 1 trial for the
treatment of RCC.

About Peloton Therapeutics

Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company
that is translating groundbreaking scientific insights into
first-in-class oral medicines for patients with cancer and other serious
or life-threatening conditions. The company's lead development program
is evaluating the only clinical-stage small-molecule inhibitor of
hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated
in the development and progression of kidney cancer and a wide variety
of other disorders. Peloton is also progressing several research
programs by building upon its success in inhibiting HIF-2α, which was
previously thought to be intractable using small molecules.

To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.

© 2018 Peloton Therapeutics, Inc.
All Rights Reserved

View Comments and Join the Discussion!